文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-FAPI-46 PET/CT 在原发性硬化性胆管炎与疑似胆管癌中的应用

68Ga-FAPI-46 PET/CT in Primary Sclerosing Cholangitis and Suspected Cholangiocarcinoma.
PubMed 文献 · J Nucl Med · 2025-11-03

本研究对18例患者(9例无确诊胆管癌的原发性硬化性胆管炎、7例无原发性硬化性胆管炎但组织学确诊胆管癌、2例两者兼有)行68Ga-FAPI-46 PET/CT,并以5例无肝病或癌症者作对照。结果显示活动性原发性硬化性胆管炎肝内成纤维细胞激活蛋白信号升高可达胆管癌水平,致胆管癌灶检测困难,但FAPI PET/CT或可用于评估原发性硬化性胆管炎活动度。

要点

  • 对照组肝内生理性FAPI信号低而均匀,SUV为1.5±0.2。
  • 胆管癌与原发性硬化性胆管炎肝内FAP-livo分别为1362±1302 mL与1286±835 mL。
  • 原发性硬化性胆管炎与胆管癌病灶SUVpeak无显著差异(P=0.72)。

核心结论

  • 活动性原发性硬化性胆管炎伴成纤维细胞激活蛋白表达升高,可达胆管癌水平;虽使相关胆管癌检测复杂化,FAPI PET/CT或可用于评估原发性硬化性胆管炎活动度。
  • 作者认为这为未来以FAPI PET/CT评估纤维化疾病进展风险或抗炎、抗纤维化治疗反应提供了依据。

研究设计与样本

  • 前瞻性单臂影像研究,纳入18例患者(9例原发性硬化性胆管炎无确诊胆管癌、7例无原发性硬化性胆管炎但组织学确诊胆管癌、2例两者兼有),另设5例无肝病或癌症诊断者作对照,均行68Ga-FAPI-46 PET/CT。
  • 结果与内镜逆行胰胆管造影、实验室指标及纤维化-4评分和白蛋白-胆红素评分进行相关性分析。

主要发现

  • 对照组肝内生理性FAPI信号低而均匀,SUV为1.5±0.2。
  • 胆管癌与原发性硬化性胆管炎肝内FAP-livo分别为1362±1302 mL与1286±835 mL。
  • 原发性硬化性胆管炎与胆管癌病灶SUVpeak无显著差异(中位数8.8[四分位距6.3]对15.0[四分位距9.2],P=0.72)。
  • 所有胆管癌及原发性硬化性胆管炎合并胆管癌患者病灶均被可靠检出;原发性硬化性胆管炎存在沿胆管分布或野状强化两种FAP信号模式。
  • FAP-livo一般与肝功能下降相关(白蛋白-胆红素评分r=0.70,P=0.04),与纤维化-4评分相关(r=0.63,P=0.08);两种影像模式亚组的临床参数存在特定差异。

关键数值与推荐

  • 生理性FAPI摄取定义为所有对照组平均SUVpeak加2个标准差。
  • 非生理性肝摄取模式经视觉分类,并计算高于生理摄取的成纤维细胞激活蛋白肝体积(FAP-livo)。

临床怎么用

  • 因活动性原发性硬化性胆管炎区域非肿瘤性FAP信号升高,额外检测胆管癌典型局灶病变不可行。
  • 作者认为FAPI PET/CT或可用于评估原发性硬化性胆管炎活动度。

局限性

  • 因活动性原发性硬化性胆管炎区域非肿瘤性FAP信号升高,额外检测胆管癌典型局灶病变不可行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease marked by fibrosis, strictures, and a high risk for developing cholangiocarcinoma (CCC). Recognition of CCC in PSC remains a diagnostic challenge. PET/CT using fibroblast activation protein inhibitors (FAPI) has emerged as a promising imaging modality in CCC, but its potential in the specific profibrotic setting of PSC has not yet been explored to the best of our knowledge. Methods: PET/CT with 68Ga-FAPI-46 was performed in 18 patients (n = 9 with PSC, without proven CCC; n = 7 without PSC, with histologically confirmed CCC; 2 with both PSC and CCC). Results were correlated with endoscopic retrograde cholangiopancreatography, laboratory parameters, and fibrosis-4 as well as albumin-bilirubin scores. Five subjects who underwent FAPI PET/CT without hepatic disease or cancer diagnosis served as controls. For PET analysis, physiologic FAPI uptake was defined as mean SUVpeak of all controls plus 2 SD. Nonphysiologic liver uptake patterns were visually classified, and a fibroblast activation protein (FAP) liver volume above physiologic uptake (FAP-livo) was calculated. Results: The physiologic liver FAP signal was low and homogeneous in controls (SUV, 1.5 + 0.2). In CCC and PSC, the liver FAP signal was elevated with a FAP-livo of 1,362 ± 1,302 mL (CCC) and 1,286 ± 835 mL (PSC). Lesion SUVpeak did not differ between PSC and CCC (median, 8.8 [interquartile range, 6.3] vs. 15.0 [interquartile range, 9.2]; P = 0.72). Lesions were reliably detected in all patients with CCC and combined PSC/CCC. In PSC, 2 distinct patterns of the FAP signal existed, either along bile ducts or with field-shaped enhancement. FAP-livo was generally associated with decreased liver function (albumin-bilirubin score; r = 0.70, P = 0.04) and fibrosis-4 (r = 0.63, P = 0.08), and clinical parameters showed specific differences in the 2 distinct imaging pattern subsets of PSC. Because of the nononcological FAP signal elevation in active PSC regions, additional detection of focal lesions typical for CCC was not feasible. Conclusion: Active PSC is associated with elevated FAP expression, up to the level of CCC. Although this complicates the detection of PSC-associated CCC, FAPI PET/CT may be used for the assessment of PSC activity. This provides a rationale for future studies using FAPI PET/CT as a measure of fibrotic disease progression risk or response to antiinflammatory and antifibrotic therapy in PSC.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Weiberg D, Wilhelm LM, Felgenhauer T, et al. 68Ga-FAPI-46 PET/CT in Primary Sclerosing Cholangitis and Suspected Cholangiocarcinoma. J Nucl Med. 2025. PMID: 40967755. doi:10.2967/jnumed.125.270434

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。